Four Decades for Justice
David R. Marriott focuses his practice on litigating complex disputes, regularly handling his clients’ most critical cases. The American Lawyer has named him a “Litigator of the Year” and repeatedly recognized him as “Litigator of the Week.” Among other accolades, he was named a “Litigation Trailblazer” by The National Law Journal and “Trial Lawyer of the Year” by Benchmark Litigation. He is a fellow of the American College of Trial Lawyers and the International Academy of Trial Lawyers.
Praised as “the go-to lawyer for high-stakes litigation” and “one of the best trial attorneys in the US,” Mr. Marriott has tried numerous state and federal cases, handled more than two dozen appeals and been involved in various forms of alternative dispute resolution. (IAM Patent 1000) Named a “Competition/Antitrust MVP” by Law360, he has taken a leading role in precedent-setting antitrust disputes, in addition to his significant experience in intellectual property, general commercial and securities matters. The Legal 500 US has repeatedly recognized Mr. Marriott as a “Leading Trial Lawyer,” noting his “versatility and trial experience” and regular representation of some of “the firm’s most high profile clients.”
Mr. Marriott’s clients have included Alcon Laboratories, AT&T, Avon Products, Bank of America, Bausch Health Companies, Bristol‑Myers Squibb, Colgate‑Palmolive, Corteva, CSX Corporation, Delta Air Lines, Eli Lilly, Forward Air, Frontier Communications, IBM, Illumina, Louis Dreyfus, Olin Corporation, NCR, Novartis, Qualcomm, Tesla, Truist Bank, Unilever, Viatris, the Massachusetts Institute of Technology and the President and Fellows of Harvard College.
Some of Mr. Marriott’s notable representations include:
Antitrust
Representing Illumina in an administrative challenge brought by the Federal Trade Commission (FTC) concerning Illumina’s $8 billion acquisition of GRAIL, a healthcare company developing a cancer screening test for 50 cancer types. In September 2022, Mr. Marriott obtained an unprecedented trial win, in which the FTC’s Chief Administrative Law Judge ruled in favor of Illumina and rejected the FTC’s merger challenge. In connection with this victory, he was recognized as The Am Law Litigation Daily’s “Litigator of the Week.”
Representing Corteva in antitrust litigation filed by the FTC and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive. Plaintiffs assert violations of the FTC Act, Clayton Act and Sherman Act, as well as various state competition and consumer protection laws. Mr. Marriott also represents Corteva in related putative class action litigation, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint.
Intellectual Property
Securities
Additional Trial Experience
Select Additional Representations
Represented Unilever PLC and its affiliates, Unilever IP Holdings B.V. and Conopco, Inc., in an action brought by its wholly owned subsidiary Ben & Jerry’s in New York federal court challenging the sale of Ben & Jerry’s Israeli business interests.
Represented the late publisher Katharine Graham (owner of The Washington Post) concerning the constitutionality of a D.C. statute that imposed a fiduciary income tax on trusts.
Mr. Marriott is the editor of New York Business Litigation (NYLJ 2013‑2018, 2020, 2022, 2024) and a contributing author and editor of Winning at Trial (ALM 2014). He has written numerous articles related to trial practice, complex litigation and ethics for New York Law Journal and the Practising Law Institute (“PLI”). Mr. Marriott also chairs PLI’s “Trial by Jury” conference and has been a repeat moderator of other PLI conferences, such as “Bet the Company Litigation.” For several years, he chaired the New York City Bar’s annual “Institute for Corporate Counsel.”
Mr. Marriott is an Adjunct Professor at New York University School of Law and a Lecturer in Law at Columbia University School of Law. He teaches antitrust, intellectual property and trial practice.
The Legal 500 US has recommended Mr. Marriott’s work in antitrust, general commercial and patent litigation, including naming him a “Leading Lawyer” for his general commercial work. Among other recognitions, Benchmark Litigation has named Mr. Marriott one of the “Top 100 Trial Lawyers in America,” a “National Star” in general commercial litigation and a “Litigation Star” in the New York area. Lawdragon has named Mr. Marriott a nationwide “Legend” and included him in its “500 Leading Lawyers in America,” “500 Leading Global Litigators” and “500 Leading Litigators in America” lists. In addition, he was recognized by the Daily Journal as a 2024 “Leading Commercial Litigator.” Mr. Marriott has been recognized by several other legal rankings publications, including The Best Lawyers in America, IAM Patent, Leaders League, LMG Life Sciences and Super Lawyers.
Mr. Marriott is admitted on the federal level, before the U.S. Supreme Court; the U.S. Courts of Appeals for the Federal, First, Second, Third, Fourth, Sixth, Ninth, Tenth and Eleventh Circuits; and the U.S. District Courts for the District of Utah, the Eastern District of New York, the Eastern District of Michigan, the Northern District of California, the Southern District of New York and the Western District of Michigan.
Mr. Marriott received a B.A. magna cum laude from Brigham Young University in 1991 and a J.D. from New York University School of Law in 1994. After graduating, he served as law clerk to Hon. Eugene F. Lynch of the U.S. District Court for the Northern District of California and to Hon. Albert J. Engel of the U.S. Court of Appeals for the Sixth Circuit.
Mr. Marriott joined Cravath in 1996 and was elected a partner in 2002.
Mr. Marriott’s clients have included Alcon Laboratories, AT&T, Avon Products, Bank of America, Bausch Health Companies, Bristol‑Myers Squibb, Colgate‑Palmolive, Corteva, CSX Corporation, Delta Air Lines, Eli Lilly, Forward Air, Frontier Communications, IBM, Illumina, Louis Dreyfus, Olin Corporation, NCR, Novartis, Qualcomm, Tesla, Truist Bank, Unilever, Viatris, the Massachusetts Institute of Technology and the President and Fellows of Harvard College.
Some of Mr. Marriott’s notable representations include:
Antitrust
Representing Illumina in an administrative challenge brought by the Federal Trade Commission (FTC) concerning Illumina’s $8 billion acquisition of GRAIL, a healthcare company developing a cancer screening test for 50 cancer types. In September 2022, Mr. Marriott obtained an unprecedented trial win, in which the FTC’s Chief Administrative Law Judge ruled in favor of Illumina and rejected the FTC’s merger challenge. In connection with this victory, he was recognized as The Am Law Litigation Daily’s “Litigator of the Week.”
Representing Corteva in antitrust litigation filed by the FTC and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive. Plaintiffs assert violations of the FTC Act, Clayton Act and Sherman Act, as well as various state competition and consumer protection laws. Mr. Marriott also represents Corteva in related putative class action litigation, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint.
Intellectual Property
Securities
Additional Trial Experience
Select Additional Representations
Represented Unilever PLC and its affiliates, Unilever IP Holdings B.V. and Conopco, Inc., in an action brought by its wholly owned subsidiary Ben & Jerry’s in New York federal court challenging the sale of Ben & Jerry’s Israeli business interests.
Represented the late publisher Katharine Graham (owner of The Washington Post) concerning the constitutionality of a D.C. statute that imposed a fiduciary income tax on trusts.
Mr. Marriott is the editor of New York Business Litigation (NYLJ 2013‑2018, 2020, 2022, 2024) and a contributing author and editor of Winning at Trial (ALM 2014). He has written numerous articles related to trial practice, complex litigation and ethics for New York Law Journal and the Practising Law Institute (“PLI”). Mr. Marriott also chairs PLI’s “Trial by Jury” conference and has been a repeat moderator of other PLI conferences, such as “Bet the Company Litigation.” For several years, he chaired the New York City Bar’s annual “Institute for Corporate Counsel.”
Mr. Marriott is an Adjunct Professor at New York University School of Law and a Lecturer in Law at Columbia University School of Law. He teaches antitrust, intellectual property and trial practice.
The Legal 500 US has recommended Mr. Marriott’s work in antitrust, general commercial and patent litigation, including naming him a “Leading Lawyer” for his general commercial work. Among other recognitions, Benchmark Litigation has named Mr. Marriott one of the “Top 100 Trial Lawyers in America,” a “National Star” in general commercial litigation and a “Litigation Star” in the New York area. Lawdragon has named Mr. Marriott a nationwide “Legend” and included him in its “500 Leading Lawyers in America,” “500 Leading Global Litigators” and “500 Leading Litigators in America” lists. In addition, he was recognized by the Daily Journal as a 2024 “Leading Commercial Litigator.” Mr. Marriott has been recognized by several other legal rankings publications, including The Best Lawyers in America, IAM Patent, Leaders League, LMG Life Sciences and Super Lawyers.
Mr. Marriott is admitted on the federal level, before the U.S. Supreme Court; the U.S. Courts of Appeals for the Federal, First, Second, Third, Fourth, Sixth, Ninth, Tenth and Eleventh Circuits; and the U.S. District Courts for the District of Utah, the Eastern District of New York, the Eastern District of Michigan, the Northern District of California, the Southern District of New York and the Western District of Michigan.
Mr. Marriott received a B.A. magna cum laude from Brigham Young University in 1991 and a J.D. from New York University School of Law in 1994. After graduating, he served as law clerk to Hon. Eugene F. Lynch of the U.S. District Court for the Northern District of California and to Hon. Albert J. Engel of the U.S. Court of Appeals for the Sixth Circuit.
Mr. Marriott joined Cravath in 1996 and was elected a partner in 2002.
American Bar Association
American Bar Foundation
ICC National Arbitration Committee (U.S. Council for International Business)
International Academy of Trial Lawyers
International Bar Association
New York City Bar Association
New York State Bar Association
The American Lawyer
Benchmark Litigation
Top 100 Trial Lawyers in America (2024)
General Commercial Star - National (2024-2017)
Litigation Star - New York (2024-2017)
Future Star (2016, 2015)
Best Lawyers in America
Euromoney Legal Media Group
Intellectual Asset Management
Law360
Lawdragon
Leaders League Innovation - Technology & Intellectual Property Report
Leaders League Litigation & International Arbitration Report
The Legal 500 US
National Law Journal
Super Lawyers - New York
Deals & Cases
January 29, 2024
On January 25, 2024, the U.S. District Court for the Southern District of New York entered judgments against appropriation artist Richard Prince and his co‑defendants Laurence Gagosian, Gagosian Gallery and Blum & Poe gallery.
Deals & Cases
September 11, 2023
Cravath represented Amgen, one of the world’s largest biopharmaceutical companies, in successfully defending against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that The Wall Street Journal described as “a rare instance” of the FTC “throwing in the towel on litigation.”
Deals & Cases
July 14, 2023
On July 13, 2023, a three judge panel for the U.S. Court of Appeals for the Third Circuit ruled in favor of Cravath clients Louis Dreyfus Company LLC (“LDC”) and Imperial Sugar Company (“Imperial Sugar”) and unanimously affirmed an earlier decision by the U.S. District Court for the District of Delaware denying U.S. Department of Justice’s (“DOJ”) request for an injunction to block LDC’s sale of the assets and business of Imperial Sugar to U.S. Sugar.
Deals & Cases
May 19, 2023
On May 11, 2023, the U.S. District Court for the Southern District of New York denied summary judgment to appropriation artist Richard Prince and his associated galleries in two copyright infringement cases brought by Cravath clients, the photographers Donald Graham and Eric McNatt, regarding works from Prince’s “New Portraits” series.
Deals & Cases
April 07, 2023
On Thursday, March 30, 2023, the U.S. District Court for the Southern District of New York granted summary judgment in favor of Cravath client Viatris (formed in 2020 from a combination of Mylan and Pfizer’s Upjohn division). The shareholder class action asserted numerous violations of the federal securities laws, all premised on other allegations related to Mylan’s marketing, pricing and classification of EpiPen as well as alleged conduct concerning generic drug price fixing and market allocation.
Accolades
March 28, 2024
On March 26, 2024, Cravath partner David R. Marriott was named to Forbes’s 2024 list of “America’s Top 200 Lawyers.” The inaugural list recognized “the finest practitioners in the profession—lawyers with stellar track records in their specialties, those who have broken barriers to emerge as leaders in their fields, and attorneys most respected by peers and clients.” Dave’s accompanying profile highlighted his experience as a “courtroom heavyweight” and his representation of clients including AT&T, Avon Products, Bank of America, Bristol‑Myers Squibb, Colgate‑Palmolive and Delta Airlines. In particular, the publication noted Dave’s achievement of “setting precedent in antitrust and intellectual property law.”
Accolades
March 14, 2024
On March 13, 2024, Benchmark Litigation honored Cravath partner David R. Marriott as its “Trial Lawyer of the Year” at the publication’s twelfth annual U.S. Awards, which were held in New York City. The awards recognize “the country’s most distinguished litigators and their firms for their exemplary work over the past twelve months.”
Activities & Publications
February 08, 2024
On February 5, 2024, The Am Law Litigation Daily interviewed Cravath partner David R. Marriot in connection with his representation of photographers Donald Graham and Eric McNatt in winning judgments against appropriation artist Richard Prince and his co defendants Laurence Gagosian, Gagosian Gallery and Blum & Poe gallery, in a case at the intersection of art, technology and copyright law.
Activities & Publications
February 08, 2024
On February 5, 2024, World Intellectual Property Review interviewed Cravath partner David R. Marriott in connection with his representation of photographers Donald Graham and Eric McNatt in winning judgments against appropriation artist Richard Prince and his co defendants Laurence Gagosian, Gagosian Gallery and Blum & Poe gallery, in a case with important implications for copyright law and its application to art and technology.
Accolades
January 31, 2024
On January 24, 2024, Cravath partner David R. Marriott was named to the Daily Journal’s 2024 list of “Leading Commercial Litigators.” The accompanying profile highlights his role in helping Amgen secure a consent order ending all litigation in connection with its pending acquisition of Horizon Therapeutics, as well as his summary judgment victory for Viatris, which was “one of the few resolutions of federal securities fraud litigation at summary judgment that ended entirely in favor of the defendants.” The profile also details Dave’s nearly 30‑year tenure at Cravath and his roles as a lecturer at Columbia University Law School and an adjunct professor at NYU School of Law.
David R. Marriott focuses his practice on litigating complex disputes, regularly handling his clients’ most critical cases. The American Lawyer has named him a “Litigator of the Year” and repeatedly recognized him as “Litigator of the Week.” Among other accolades, he was named a “Litigation Trailblazer” by The National Law Journal and “Trial Lawyer of the Year” by Benchmark Litigation. He is a fellow of the American College of Trial Lawyers and the International Academy of Trial Lawyers.
Praised as “the go-to lawyer for high-stakes litigation” and “one of the best trial attorneys in the US,” Mr. Marriott has tried numerous state and federal cases, handled more than two dozen appeals and been involved in various forms of alternative dispute resolution. (IAM Patent 1000) Named a “Competition/Antitrust MVP” by Law360, he has taken a leading role in precedent-setting antitrust disputes, in addition to his significant experience in intellectual property, general commercial and securities matters. The Legal 500 US has repeatedly recognized Mr. Marriott as a “Leading Trial Lawyer,” noting his “versatility and trial experience” and regular representation of some of “the firm’s most high profile clients.”
Mr. Marriott’s clients have included Alcon Laboratories, AT&T, Avon Products, Bank of America, Bausch Health Companies, Bristol‑Myers Squibb, Colgate‑Palmolive, Corteva, CSX Corporation, Delta Air Lines, Eli Lilly, Forward Air, Frontier Communications, IBM, Illumina, Louis Dreyfus, Olin Corporation, NCR, Novartis, Qualcomm, Tesla, Truist Bank, Unilever, Viatris, the Massachusetts Institute of Technology and the President and Fellows of Harvard College.
Some of Mr. Marriott’s notable representations include:
Antitrust
Representing Illumina in an administrative challenge brought by the Federal Trade Commission (FTC) concerning Illumina’s $8 billion acquisition of GRAIL, a healthcare company developing a cancer screening test for 50 cancer types. In September 2022, Mr. Marriott obtained an unprecedented trial win, in which the FTC’s Chief Administrative Law Judge ruled in favor of Illumina and rejected the FTC’s merger challenge. In connection with this victory, he was recognized as The Am Law Litigation Daily’s “Litigator of the Week.”
Representing Corteva in antitrust litigation filed by the FTC and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive. Plaintiffs assert violations of the FTC Act, Clayton Act and Sherman Act, as well as various state competition and consumer protection laws. Mr. Marriott also represents Corteva in related putative class action litigation, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint.
Intellectual Property
Securities
Additional Trial Experience
Select Additional Representations
Represented Unilever PLC and its affiliates, Unilever IP Holdings B.V. and Conopco, Inc., in an action brought by its wholly owned subsidiary Ben & Jerry’s in New York federal court challenging the sale of Ben & Jerry’s Israeli business interests.
Represented the late publisher Katharine Graham (owner of The Washington Post) concerning the constitutionality of a D.C. statute that imposed a fiduciary income tax on trusts.
Mr. Marriott is the editor of New York Business Litigation (NYLJ 2013‑2018, 2020, 2022, 2024) and a contributing author and editor of Winning at Trial (ALM 2014). He has written numerous articles related to trial practice, complex litigation and ethics for New York Law Journal and the Practising Law Institute (“PLI”). Mr. Marriott also chairs PLI’s “Trial by Jury” conference and has been a repeat moderator of other PLI conferences, such as “Bet the Company Litigation.” For several years, he chaired the New York City Bar’s annual “Institute for Corporate Counsel.”
Mr. Marriott is an Adjunct Professor at New York University School of Law and a Lecturer in Law at Columbia University School of Law. He teaches antitrust, intellectual property and trial practice.
The Legal 500 US has recommended Mr. Marriott’s work in antitrust, general commercial and patent litigation, including naming him a “Leading Lawyer” for his general commercial work. Among other recognitions, Benchmark Litigation has named Mr. Marriott one of the “Top 100 Trial Lawyers in America,” a “National Star” in general commercial litigation and a “Litigation Star” in the New York area. Lawdragon has named Mr. Marriott a nationwide “Legend” and included him in its “500 Leading Lawyers in America,” “500 Leading Global Litigators” and “500 Leading Litigators in America” lists. In addition, he was recognized by the Daily Journal as a 2024 “Leading Commercial Litigator.” Mr. Marriott has been recognized by several other legal rankings publications, including The Best Lawyers in America, IAM Patent, Leaders League, LMG Life Sciences and Super Lawyers.
Mr. Marriott is admitted on the federal level, before the U.S. Supreme Court; the U.S. Courts of Appeals for the Federal, First, Second, Third, Fourth, Sixth, Ninth, Tenth and Eleventh Circuits; and the U.S. District Courts for the District of Utah, the Eastern District of New York, the Eastern District of Michigan, the Northern District of California, the Southern District of New York and the Western District of Michigan.
Mr. Marriott received a B.A. magna cum laude from Brigham Young University in 1991 and a J.D. from New York University School of Law in 1994. After graduating, he served as law clerk to Hon. Eugene F. Lynch of the U.S. District Court for the Northern District of California and to Hon. Albert J. Engel of the U.S. Court of Appeals for the Sixth Circuit.
Mr. Marriott joined Cravath in 1996 and was elected a partner in 2002.
Mr. Marriott’s clients have included Alcon Laboratories, AT&T, Avon Products, Bank of America, Bausch Health Companies, Bristol‑Myers Squibb, Colgate‑Palmolive, Corteva, CSX Corporation, Delta Air Lines, Eli Lilly, Forward Air, Frontier Communications, IBM, Illumina, Louis Dreyfus, Olin Corporation, NCR, Novartis, Qualcomm, Tesla, Truist Bank, Unilever, Viatris, the Massachusetts Institute of Technology and the President and Fellows of Harvard College.
Some of Mr. Marriott’s notable representations include:
Antitrust
Representing Illumina in an administrative challenge brought by the Federal Trade Commission (FTC) concerning Illumina’s $8 billion acquisition of GRAIL, a healthcare company developing a cancer screening test for 50 cancer types. In September 2022, Mr. Marriott obtained an unprecedented trial win, in which the FTC’s Chief Administrative Law Judge ruled in favor of Illumina and rejected the FTC’s merger challenge. In connection with this victory, he was recognized as The Am Law Litigation Daily’s “Litigator of the Week.”
Representing Corteva in antitrust litigation filed by the FTC and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive. Plaintiffs assert violations of the FTC Act, Clayton Act and Sherman Act, as well as various state competition and consumer protection laws. Mr. Marriott also represents Corteva in related putative class action litigation, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint.
Intellectual Property
Securities
Additional Trial Experience
Select Additional Representations
Represented Unilever PLC and its affiliates, Unilever IP Holdings B.V. and Conopco, Inc., in an action brought by its wholly owned subsidiary Ben & Jerry’s in New York federal court challenging the sale of Ben & Jerry’s Israeli business interests.
Represented the late publisher Katharine Graham (owner of The Washington Post) concerning the constitutionality of a D.C. statute that imposed a fiduciary income tax on trusts.
Mr. Marriott is the editor of New York Business Litigation (NYLJ 2013‑2018, 2020, 2022, 2024) and a contributing author and editor of Winning at Trial (ALM 2014). He has written numerous articles related to trial practice, complex litigation and ethics for New York Law Journal and the Practising Law Institute (“PLI”). Mr. Marriott also chairs PLI’s “Trial by Jury” conference and has been a repeat moderator of other PLI conferences, such as “Bet the Company Litigation.” For several years, he chaired the New York City Bar’s annual “Institute for Corporate Counsel.”
Mr. Marriott is an Adjunct Professor at New York University School of Law and a Lecturer in Law at Columbia University School of Law. He teaches antitrust, intellectual property and trial practice.
The Legal 500 US has recommended Mr. Marriott’s work in antitrust, general commercial and patent litigation, including naming him a “Leading Lawyer” for his general commercial work. Among other recognitions, Benchmark Litigation has named Mr. Marriott one of the “Top 100 Trial Lawyers in America,” a “National Star” in general commercial litigation and a “Litigation Star” in the New York area. Lawdragon has named Mr. Marriott a nationwide “Legend” and included him in its “500 Leading Lawyers in America,” “500 Leading Global Litigators” and “500 Leading Litigators in America” lists. In addition, he was recognized by the Daily Journal as a 2024 “Leading Commercial Litigator.” Mr. Marriott has been recognized by several other legal rankings publications, including The Best Lawyers in America, IAM Patent, Leaders League, LMG Life Sciences and Super Lawyers.
Mr. Marriott is admitted on the federal level, before the U.S. Supreme Court; the U.S. Courts of Appeals for the Federal, First, Second, Third, Fourth, Sixth, Ninth, Tenth and Eleventh Circuits; and the U.S. District Courts for the District of Utah, the Eastern District of New York, the Eastern District of Michigan, the Northern District of California, the Southern District of New York and the Western District of Michigan.
Mr. Marriott received a B.A. magna cum laude from Brigham Young University in 1991 and a J.D. from New York University School of Law in 1994. After graduating, he served as law clerk to Hon. Eugene F. Lynch of the U.S. District Court for the Northern District of California and to Hon. Albert J. Engel of the U.S. Court of Appeals for the Sixth Circuit.
Mr. Marriott joined Cravath in 1996 and was elected a partner in 2002.
American Bar Association
American Bar Foundation
ICC National Arbitration Committee (U.S. Council for International Business)
International Academy of Trial Lawyers
International Bar Association
New York City Bar Association
New York State Bar Association
The American Lawyer
Benchmark Litigation
Top 100 Trial Lawyers in America (2024)
General Commercial Star - National (2024-2017)
Litigation Star - New York (2024-2017)
Future Star (2016, 2015)
Best Lawyers in America
Euromoney Legal Media Group
Intellectual Asset Management
Law360
Lawdragon
Leaders League Innovation - Technology & Intellectual Property Report
Leaders League Litigation & International Arbitration Report
The Legal 500 US
National Law Journal
Super Lawyers - New York
Deals & Cases
January 29, 2024
On January 25, 2024, the U.S. District Court for the Southern District of New York entered judgments against appropriation artist Richard Prince and his co‑defendants Laurence Gagosian, Gagosian Gallery and Blum & Poe gallery.
Deals & Cases
September 11, 2023
Cravath represented Amgen, one of the world’s largest biopharmaceutical companies, in successfully defending against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that The Wall Street Journal described as “a rare instance” of the FTC “throwing in the towel on litigation.”
Deals & Cases
July 14, 2023
On July 13, 2023, a three judge panel for the U.S. Court of Appeals for the Third Circuit ruled in favor of Cravath clients Louis Dreyfus Company LLC (“LDC”) and Imperial Sugar Company (“Imperial Sugar”) and unanimously affirmed an earlier decision by the U.S. District Court for the District of Delaware denying U.S. Department of Justice’s (“DOJ”) request for an injunction to block LDC’s sale of the assets and business of Imperial Sugar to U.S. Sugar.
Deals & Cases
May 19, 2023
On May 11, 2023, the U.S. District Court for the Southern District of New York denied summary judgment to appropriation artist Richard Prince and his associated galleries in two copyright infringement cases brought by Cravath clients, the photographers Donald Graham and Eric McNatt, regarding works from Prince’s “New Portraits” series.
Deals & Cases
April 07, 2023
On Thursday, March 30, 2023, the U.S. District Court for the Southern District of New York granted summary judgment in favor of Cravath client Viatris (formed in 2020 from a combination of Mylan and Pfizer’s Upjohn division). The shareholder class action asserted numerous violations of the federal securities laws, all premised on other allegations related to Mylan’s marketing, pricing and classification of EpiPen as well as alleged conduct concerning generic drug price fixing and market allocation.
Accolades
March 28, 2024
On March 26, 2024, Cravath partner David R. Marriott was named to Forbes’s 2024 list of “America’s Top 200 Lawyers.” The inaugural list recognized “the finest practitioners in the profession—lawyers with stellar track records in their specialties, those who have broken barriers to emerge as leaders in their fields, and attorneys most respected by peers and clients.” Dave’s accompanying profile highlighted his experience as a “courtroom heavyweight” and his representation of clients including AT&T, Avon Products, Bank of America, Bristol‑Myers Squibb, Colgate‑Palmolive and Delta Airlines. In particular, the publication noted Dave’s achievement of “setting precedent in antitrust and intellectual property law.”
Accolades
March 14, 2024
On March 13, 2024, Benchmark Litigation honored Cravath partner David R. Marriott as its “Trial Lawyer of the Year” at the publication’s twelfth annual U.S. Awards, which were held in New York City. The awards recognize “the country’s most distinguished litigators and their firms for their exemplary work over the past twelve months.”
Activities & Publications
February 08, 2024
On February 5, 2024, The Am Law Litigation Daily interviewed Cravath partner David R. Marriot in connection with his representation of photographers Donald Graham and Eric McNatt in winning judgments against appropriation artist Richard Prince and his co defendants Laurence Gagosian, Gagosian Gallery and Blum & Poe gallery, in a case at the intersection of art, technology and copyright law.
Activities & Publications
February 08, 2024
On February 5, 2024, World Intellectual Property Review interviewed Cravath partner David R. Marriott in connection with his representation of photographers Donald Graham and Eric McNatt in winning judgments against appropriation artist Richard Prince and his co defendants Laurence Gagosian, Gagosian Gallery and Blum & Poe gallery, in a case with important implications for copyright law and its application to art and technology.
Accolades
January 31, 2024
On January 24, 2024, Cravath partner David R. Marriott was named to the Daily Journal’s 2024 list of “Leading Commercial Litigators.” The accompanying profile highlights his role in helping Amgen secure a consent order ending all litigation in connection with its pending acquisition of Horizon Therapeutics, as well as his summary judgment victory for Viatris, which was “one of the few resolutions of federal securities fraud litigation at summary judgment that ended entirely in favor of the defendants.” The profile also details Dave’s nearly 30‑year tenure at Cravath and his roles as a lecturer at Columbia University Law School and an adjunct professor at NYU School of Law.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.